Servier gains rights to Spectrum drugs in Canada

13 January 2016
2019_biotech_test_vial_discovery_big

US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a strategic partnership with the Canadian subsidiary of French privately-held drugmaker Servier for the marketing of several of its drug products.

As part of this partnership, Spectrum will grant the exclusive rights to develop and commercialize in Canada a franchise of four Spectrum hemato-oncology drugs: Zevalin (ibritumomab tiuxetan), Folotyn (pralatrexate), Beleodaq (belinostat) and Marqibo (vinCRIStine sulfate Liposome). Spectrum will receive $6 million in upfront payments, plus development milestone payments and royalties based on net product sales.

“We are pleased to announce this strategic partnership with Servier, a leading company in Canada,” said Rajesh Shrotriya, chairman and chief executive of Spectrum Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology